Related Experiment Video
Updated: Jun 15, 2026
05:05
Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
Published on: June 17, 2025
Pemphigus, analysis of 155 patients.
D Mimouni1, H Bar, M Gdalevich
1Department of Dermatology, Rabin Medical Center, Petah Tiqwa, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Summary
Pemphigus vulgaris outcomes are worse for young patients (<40 years), Sephardic Jews, and those with mucosal involvement. Early remission is a good prognostic factor for this autoimmune blistering disease.
Area of Science:
- Autoimmune diseases
- Dermatology
- Immunology
Background:
- Pemphigus vulgaris is a chronic autoimmune blistering disease.
- Immunomodulatory agents have expanded treatment options in recent decades.
- Long-term pemphigus outcomes and prognostic factors require further investigation.
Purpose of the Study:
- To analyze the long-term course and identify prognostic factors in pemphigus vulgaris patients.
- To evaluate disease progression and outcomes over an extended period.
Main Methods:
- Retrospective analysis of 155 pemphigus patients followed from 1976 to 2004.
- Data collection included patient files and telephone interviews.
- Statistical analysis employed Pearson correlation, Fisher exact test, and logistic regression.
Main Results:
- Younger age at onset (<40 years), Sephardic Jewish origin, mucosal involvement, and frequent relapses predicted poor outcomes.
- Achieving a primary remission longer than one year was a favorable prognostic indicator.
- Mortality was not directly linked to pemphigus or its treatments.
Conclusions:
- Pemphigus vulgaris prognosis is negatively impacted by early-onset disease, Sephardic Jewish ethnicity, and mucosal involvement.
- Treatment response and disease recurrence are critical indicators of patient outcome.
- Observed lower mortality may be attributed to modern immunomodulatory therapies.
